🇺🇸 FDA
Pipeline program

Sodium phenylbutyrate

STUDY25060137

Phase 1 small_molecule active

Quick answer

Sodium phenylbutyrate for Combined D,L-2-hydroxyglutaric Aciduria is a Phase 1 program (small_molecule) at ZEVRA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
ZEVRA THERAPEUTICS, INC.
Indication
Combined D,L-2-hydroxyglutaric Aciduria
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials